Marleau Sylvie, Mulumba Mukandila, Lamontagne Daniel, Ong Huy
Faculty of Pharmacy, Université de Montréal, Québec, Canada, H3T 1J4.
Cardiovasc Res. 2006 Jan;69(1):26-35. doi: 10.1016/j.cardiores.2005.08.022. Epub 2005 Oct 10.
Ischemic and nonischemic cardiomyopathies are associated with significant morbidity and mortality in industrialized countries. Cardiomyopathies of primary origin, and more specifically the dilated form of the disease, have been associated with a number of gene defects in cytoskeletal, membrane, and sarcomeric proteins. Cardiomyopathies of secondary origin such as ischemic cardiomyopathy remain the leading cause of left ventricular systolic dysfunction and heart failure. Among novel strategies to improve cardiac function in heart failure, treatment with growth hormone, insulin growth factor-1 (IGF-1), and natural and synthetic growth hormone-releasing peptides such as ghrelin and hexarelin have been explored. The present review focuses on the issues involved in the use of exogenous growth hormone and its releasing peptides in experimental animal models of chronic heart failure and in clinical studies on cardiomyopathic patients as potential releasing peptides for the treatment of chronic heart failure developing as a consequence of cardiomyopathy.
在工业化国家，缺血性和非缺血性心肌病与显著的发病率和死亡率相关。原发性心肌病，尤其是扩张型心肌病，与细胞骨架、膜和肌节蛋白中的一些基因缺陷有关。继发性心肌病，如缺血性心肌病，仍然是左心室收缩功能障碍和心力衰竭的主要原因。在改善心力衰竭心脏功能的新策略中，人们已经探索了使用生长激素、胰岛素样生长因子-1（IGF-1）以及天然和合成的生长激素释放肽，如胃饥饿素和六元瑞林进行治疗。本综述重点关注在慢性心力衰竭实验动物模型以及心肌病患者临床研究中使用外源性生长激素及其释放肽作为治疗因心肌病导致的慢性心力衰竭的潜在释放肽所涉及的问题。
